Related Experiment Video
Updated: May 2, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
1.5K
[New drugs in rheumatology]
1Lehrstuhl für Innere Medizin mit Schwerpunkt Rheumatologie, Justus-Liebig-Universität Gießen, Gießen, Deutschland, rheumatologie@kerckhoff-klinik.de.
Der Internist
|March 1, 2014
Summary
Novel therapeutic advances in rheumatology are rare due to trial data. New drugs like rituximab offer welcome treatment options for complex autoimmune diseases and inflammatory conditions.
Area of Science:
- Rheumatology and clinical immunology.
- Drug development and therapeutic strategies.
Context:
- Monitoring drug development via clinicaltrials.gov reduces surprises.
- Individual variability and rare diseases in rheumatology pose challenges for novel drug introduction.
- Post-approval, strict clinical trial criteria limit patient populations.
Purpose:
- To highlight the challenges and welcome the introduction of novel drugs in rheumatology.
- To discuss the implications of new therapeutic agents in managing complex rheumatic diseases.
Summary:
- Novel treatments are crucial as clinical trials only represent a fraction of patients.
- Examples include rituximab for ANCA-associated vasculitis, ustekinumab for psoriatic arthritis, and IL-1 inhibitors for gout.
- Future therapies include kinase and macrophage inhibitors.
Impact:
- Facilitates the integration of new, effective treatments into clinical practice.
- Addresses unmet needs in managing diverse and rare rheumatological conditions.
- Expands therapeutic options for patients with autoimmune and inflammatory diseases.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:21Rheumatic Heart Disease III: Medical Management
544
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
544
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705